Literature DB >> 7923888

Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis.

K D Sekiyama1, M Yoshiba, A W Thomson.   

Abstract

Fulminant hepatic failure (FHF) is characterized by massive necroinflammation of the liver tissue and is associated with high mortality. Serum concentrations of IL-1 beta, tumour necrosis factor-alpha (TNF-alpha), IL-6 and IL-1 receptor antagonist (IL-1Ra) were measured in 30 patients with FHF and in 23 patients with acute hepatitis (AH) before start of treatment and in 23 healthy controls. Levels of all four molecules were increased significantly in FHF compared with AH, in which values were higher than in the healthy controls. High serum levels of IL-1 beta and a significantly reduced ratio of IL-1Ra to IL-1 beta (IL-1Ra/IL-1 beta) were observed in FHF patients who subsequently died compared with subjects who survived. TNF-alpha and IL-6 concentrations were correlated with levels of human hepatocyte growth factor (hHGF), an index of hepatocyte regeneration. Although serum cytokine levels varied considerably between patients within each group studied, it is suggested that the striking elevation in proinflammatory cytokine levels in FHF may reflect both the insufficiency of hepatitis virus elimination and a failure to control a vicious cytokine cascade leading to overwhelming hepatocyte destruction rather than regeneration. The high cytokine levels observed in these patients and the significantly elevated IL-1Ra/IL-1 beta ratio in FHF patients who survived compared with those who did not suggest the possible therapeutic use of cytokine antagonists for the control of this life-threatening disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923888      PMCID: PMC1534161          DOI: 10.1111/j.1365-2249.1994.tb06609.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Production of interleukin-1-receptor antagonist during experimental endotoxaemia.

Authors:  E V Granowitz; A A Santos; D D Poutsiaka; J G Cannon; D W Wilmore; S M Wolff; C A Dinarello
Journal:  Lancet       Date:  1991-12-07       Impact factor: 79.321

Review 2.  The role of interleukin-1 in disease.

Authors:  C A Dinarello; S M Wolff
Journal:  N Engl J Med       Date:  1993-01-14       Impact factor: 91.245

3.  Circulating interleukin-1 and tumor necrosis factor antagonists in liver disease.

Authors:  H Tilg; W Vogel; C J Wiedermann; L Shapiro; M Herold; G Judmaier; C A Dinarello
Journal:  Hepatology       Date:  1993-11       Impact factor: 17.425

4.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

Authors:  E Fischer; M A Marano; K J Van Zee; C S Rock; A S Hawes; W A Thompson; L DeForge; J S Kenney; D G Remick; D C Bloedow
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

5.  Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease.

Authors:  E Fischer; K J Van Zee; M A Marano; C S Rock; J S Kenney; D D Poutsiaka; C A Dinarello; S F Lowry; L L Moldawer
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

6.  Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo.

Authors:  Y Ishiki; H Ohnishi; Y Muto; K Matsumoto; T Nakamura
Journal:  Hepatology       Date:  1992-11       Impact factor: 17.425

7.  Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy.

Authors:  P Akerman; P Cote; S Q Yang; C McClain; S Nelson; G J Bagby; A M Diehl
Journal:  Am J Physiol       Date:  1992-10

8.  Serum interleukin 6 levels in patients with chronic hepatitis B.

Authors:  S Kakumu; T Shinagawa; T Ishikawa; K Yoshioka; T Wakita; Y Ito; M Takayanagi; N Ida
Journal:  Am J Gastroenterol       Date:  1991-12       Impact factor: 10.864

Review 9.  Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.

Authors:  C A Dinarello; R C Thompson
Journal:  Immunol Today       Date:  1991-11

10.  Development of reliable artificial liver support (ALS)--plasma exchange in combination with hemodiafiltration using high-performance membranes.

Authors:  M Yoshiba; K Sekiyama; Y Iwamura; F Sugata
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

View more
  46 in total

1.  Protective effect of recombinant human IL-1Ra on CCl4-induced acute liver injury in mice.

Authors:  Run-Zhi Zhu; Di Xiang; Chao Xie; Jing-Jing Li; Jian-Jun Hu; Hong-Lin He; Yun-Sheng Yuan; Jin Gao; Wei Han; Yan Yu
Journal:  World J Gastroenterol       Date:  2010-06-14       Impact factor: 5.742

2.  Effect of hepatocyte apoptosis induced by TNF-alpha on acute severe hepatitis in mouse models.

Authors:  Guo-Qing Zang; Xia-Qiu Zhou; Hong Yu; Qing Xie; Guo-Ming Zhao; Bin Wang; Qing Guo; Yue-Qin Xiang; Dan Liao
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

3.  Pro-inflammatory cytokine release and mediation of the acute phase protein response in fulminant hepatic failure.

Authors:  S J Wigmore; T S Walsh; A Lee; J A Ross
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

4.  N-acetylcysteine attenuates cerebral complications of non-acetaminophen-induced acute liver failure in mice: antioxidant and anti-inflammatory mechanisms.

Authors:  Chantal Bémeur; Javier Vaquero; Paul Desjardins; Roger F Butterworth
Journal:  Metab Brain Dis       Date:  2010-04-30       Impact factor: 3.584

5.  Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1β in idiopathic pulmonary fibrosis.

Authors:  N P Barlo; C H M van Moorsel; N M Korthagen; M Heron; G T Rijkers; H J T Ruven; J M M van den Bosch; J C Grutters
Journal:  Clin Exp Immunol       Date:  2011-12       Impact factor: 4.330

6.  Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist.

Authors:  Masahiro Shinoda; Arno W Tilles; Go Wakabayashi; Atsushi Takayanagi; Hirohisa Harada; Hideaki Obara; Kazuhiro Suganuma; François Berthiaume; Motohide Shimazu; Nobuyoshi Shimizu; Masaki Kitajima; Ronald G Tompkins; Mehmet Toner; Martin L Yarmush
Journal:  Tissue Eng       Date:  2006-05

7.  Role of monocytes and macrophages in experimental and human acute liver failure.

Authors:  Lucia A Possamai; Charalambos Gustav Antoniades; Quentin M Anstee; Alberto Quaglia; Diego Vergani; Mark Thursz; Julia Wendon
Journal:  World J Gastroenterol       Date:  2010-04-21       Impact factor: 5.742

8.  Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis.

Authors:  L Gramantieri; A Casali; D Trerè; S Gaiani; F Piscaglia; P Chieco; B Cola; L Bolondi
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

9.  Combined mesenchymal stem cell transplantation and interleukin-1 receptor antagonism after partial hepatectomy.

Authors:  Jian-Feng Sang; Xiao-Lei Shi; Bing Han; Xu Huang; Tao Huang; Hao-Zhen Ren; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

10.  Association of tumor necrosis factor-alpha gene promoter polymorphisms with acute viral hepatitis in the Indian population.

Authors:  Shashideep Singhal; Indu Kohaar; Mausumi Bharadwaj; Deepak K Shukla; Bhudev C Das; Premashis Kar
Journal:  Dig Dis Sci       Date:  2009-04-24       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.